François Guérard

Dr. François Guérard

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RERomain Eychenne
Romain Eychenne
MCMichel Chérel
Michel Chérel
FHferid haddad
ferid haddad
FGFrançois Guérard
François Guérard
JGJean François Gestin
Jean François Gestin
Among all existing radionuclides, only a few are of interest for therapeutic applications and more specifically for targeted alpha therapy (TAT). From this selection, actinium-225, astatine-211, bismuth-212, bismuth-213, lead-212, radium-223, terbium-149 and thorium-227 are considered as the most suitable. Despite common general features, they all have their own physical characteristics that make them singular and so promising for TAT. These radionuclides were largely studied over the last two decades, leading to a better knowledge of their production process and chemical behavior, allowing for an increasing number of biological evaluations. The aim of this review is to summarize the main properties of these eight chosen radionuclides. An overview from their availability to the resulting clinical studies, by way of chemical design and preclinical studies is discussed.

1 February 2013 in Cancer Biotherapy and Radiopharmaceuticals
Verified
Journal Article
Closed access
FGFrançois Guérard
François Guérard
JGJean-François Gestin
Jean-François Gestin
MBMartin W. Brechbiel
Martin W. Brechbiel
(211)At is a promising radionuclide for α-particle therapy of cancers. Its physical characteristics make this radionuclide particularly interesting to consider when bound to cancer-targeting biomolecules for the treatment of microscopic tumors. (211)At is produced by cyclotron irradiation of (209)Bi with α-particles accelerated at ~28 MeV and can be obtained in high radionuclidic purity after isolation from the target. Its chemistry resembles iodine, but there is also a tendency to behave as a metalloid. However, the chemical behavior of astatine has not yet been clearly established, primarily due to the lack of any stable isotopes of this element, which precludes the use of conventional analytical techniques for its characterization. There are also only a limited number of research centers that have been able to produce this element in sufficient amounts to carry out extensive investigations. Despite these difficulties, chemical reactions typically used with iodine can be performed, and a number of biomolecules of interest have been labeled with (211)At. However, most of these compounds exhibit unacceptable instability in vivo due to the weakness of the astatine-biomolecule bond. Nonetheless, several compounds have shown high potential for the treatment of cancers in vitro and in several animal models, thus providing a promising basis that has allowed initiation of the first two clinical studies.

12 December 2012 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
FGFrançois Guérard
François Guérard
YLYong-Sok Lee
Yong-Sok Lee
RTRaphaël Tripier
Raphaël Tripier
LSLawrence P. Szajek
Lawrence P. Szajek
JDJeffrey Deschamps
Jeffrey Deschamps
MBMartin W. Brechbiel
Martin W. Brechbiel
Crystallography, quantum chemistry and potentiometry of Zr( iv ) hydroxamate complexes: a combination of tools to improve the development of 89 Zr chelation for nuclear imaging.

5 August 2021 in Accounts of Chemical Research
Verified
Journal Article
Closed access
FGFrançois Guérard
François Guérard
CMClémence Maingueneau
Clémence Maingueneau
LLLu Liu
Lu Liu
RERomain Eychenne
Romain Eychenne
JGJean-François Gestin
Jean-François Gestin
NGNicolas Galland
Nicolas Galland

14 February 2020 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
JPJustine Perrin
Justine Perrin
MCMarisa Capitao
Marisa Capitao
MMMarie Mougin-Degraef
Marie Mougin-Degraef
FGFrançois Guérard
François Guérard
AFAlain Faivre-Chauvet
Alain Faivre-Chauvet
JBJacques Barbet
Jacques Barbet
The impressive development of cancer immunotherapy in the last few years originates from a more precise understanding of control mechanisms in the immune system leading to the discovery of new targets and new therapeutic tools. Since different stages of disease progression elicit different local and systemic inflammatory responses, the ability to longitudinally interrogate the migration and expansion of immune cells throughout the whole body will greatly facilitate disease characterization and guide selection of appropriate treatment regiments. While using radiolabeled white blood cells to detect inflammatory lesions has been a classical nuclear medicine technique for years, new non-invasive methods for monitoring the distribution and migration of biologically active cells in living organisms have emerged. They are designed to improve detection sensitivity and allow for a better preservation of cell activity and integrity. These methods include the monitoring of therapeutic cells but also of all cells related to a specific disease or therapeutic approach. Labeling of therapeutic cells for imaging may be performed in vitro, with some limitations on sensitivity and duration of observation. Alternatively, in vivo cell tracking may be performed by genetically engineering cells or mice so that may be revealed through imaging. In addition, SPECT or PET imaging based on monoclonal antibodies has been used to detect tumors in the human body for years. They may be used to detect and quantify the presence of specific cells within cancer lesions. These methods have been the object of several recent reviews that have concentrated on technical aspects, stressing the differences between direct and indirect labeling. They are briefly described here by distinguishing ex vivo (labeling cells with paramagnetic, radioactive, or fluorescent tracers) and in vivo (in vivo capture of injected radioactive, fluorescent or luminescent tracers, or by using labeled antibodies, ligands, or pre-targeted clickable substrates) imaging methods. This review focuses on cell tracking in specific therapeutic applications, namely cell therapy, and particularly CAR (Chimeric Antigen Receptor) T-cell therapy, which is a fast-growing research field with various therapeutic indications. The potential impact of imaging on the progress of these new therapeutic modalities is discussed.

16 April 2014 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
FGFrançois Guérard
François Guérard
YLYong‐Sok Lee
Yong‐Sok Lee
MBMartin W. Brechbiel
Martin W. Brechbiel